ICD10 code of Essential Thrombocythemia and ICD9 code

The ICD-10 code for Essential Thrombocythemia is D47.3, while the legacy ICD-9 code used for clinical documentation is 238.4. These classification codes are essential for medical billing, diagnostic tracking, and international health reporting for this specific myeloproliferative neoplasm.

What is Essential Thrombocythemia?

Essential Thrombocythemia is a chronic blood disorder characterized by the overproduction of platelets by megakaryocytes in the bone marrow. This condition, which currently affects 325 members of the DiseaseMaps.org community, often leads to an increased risk of blood clots (thrombosis) or, conversely, bleeding complications. Understanding that Essential Thrombocythemia is a lifelong condition helps patients and caregivers better navigate long-term management strategies.

How is Essential Thrombocythemia diagnosed and managed?

Diagnosis typically involves a combination of complete blood counts (CBC), bone marrow biopsies, and genetic testing for mutations such as JAK2, CALR, or MPL. Management focuses on reducing the risk of vascular events. Standard treatment protocols for Essential Thrombocythemia include:

• Low-dose aspirin: Frequently prescribed to reduce the risk of clotting.


• Cytoreductive therapy: Medications like Hydrea (hydroxyurea) are used to lower platelet counts in high-risk patients.


• Symptom monitoring: Active management of fatigue, bone pain, and visual disturbances is crucial for quality of life.

What is the emotional impact of living with Essential Thrombocythemia?

Living with a diagnosis like Essential Thrombocythemia can be isolating, especially given the invisible nature of symptoms like persistent fatigue and bone pain. Many patients find that connecting with others who share the same diagnosis helps alleviate the psychological burden. With 325 individuals currently sharing their experiences on DiseaseMaps.org, peer support remains a vital component of holistic care for those managing Essential Thrombocythemia.

Next steps

• Consult a hematologist specializing in myeloproliferative neoplasms (MPNs) to discuss your specific risk profile.


• Monitor for new symptoms such as unexplained bruising or changes in vision and report them to your physician immediately.


• Join the DiseaseMaps.org community to share experiences and find support from others living with Essential Thrombocythemia.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; always consult with your healthcare provider regarding diagnosis and treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD) - Essential Thrombocythemia


• Orphanet (ORPHA:838) - Essential Thrombocythemia


• OMIM (Online Mendelian Inheritance in Man) - Entry #187950


• MPN Research Foundation - Patient Resources